Introduction
Prostate cancer is the most common malignancy affecting men in the United States, and is the second leading cause of cancer death, with approximately 20% of diagnosed men expected to die of the disease. 1, 2 Prostate cancer is frequently hormone dependent, and therefore antiandrogen therapy has been an important aspect of treatment for patients with prostate cancer. While initial management of prostate cancer with antiandrogen therapy has been primarily limited to patients with metastatic disease, androgen ablation therapy has been used increasingly over the past decade as neoadjuvant therapy in conjunction with surgery, radiation therapy and prostate brachytherapy.
Multiple studies have examined the role of angiogenesis in tumour growth and metastasis and have recently discovered links between antiandrogen therapy, radiation therapy and angiogenesis, which have exciting implications for the treatment of prostate cancer. The aim of this article is to examine the effects of hormonal therapy on angiogenesis and focus on this process as a mechanism that may account, at least partially, for the additive effect seen when hormonal and radiation therapies are used in combination.
Methods
Data for this review were identified by searches of MEDLINE, Current Contents, PubMed and references from relevant articles using the search terms 'hormonal therapy', 'radiation therapy', 'antiangiogenesis', 'VEGF' and 'prostate cancer'. Only papers published in English between 1980 and 2004 were included.
Current treatment modalities in prostate cancer
Currently, the appropriate treatment of adenocarcinoma confined to the prostate at the time of diagnosis (stages T1-T2) includes either radical prostatectomy or externalbeam radiation therapy (EBRT)/intensity-modulated radiation therapy (IMRT), with prostate brachytherapy used as monotherapy for selected patients (Gleason score o7, prostate-specific antigen level o10 ng/ml) or in combination with EBRT/IMRT for intermediate-risk patients. EBRT also plays a major role in the treatment of locally advanced (T3-T4) prostate cancer. 3 Androgen deprivation therapy is being used with increasing frequency as primary monotherapy in appropriately selected patients with localised disease. 4 The efficacy of adjuvant hormonal therapy with radiation therapy has been demonstrated in several studies. 5 
Angiogenesis
It is known that multiple angiogenic cytokines, including basic fibroblastic growth factor (bFGF), transforming growth factor-alpha, transforming growth factor-beta, tumour necrosis factor-alpha and vascular endothelial growth factor (VEGF), are expressed in normal prostate cells. 6 Among these, perhaps the most significant is VEGF, the most potent and specific growth factor for endothelial cells. 7, 8 Angiogenic factors such as VEGF and bFGF are expressed in many human prostate cancer cell lines 9, 10 and VEGF expression is induced in many cancer cells as a result of multiple genetic alterations, including P53 and PTEN loss of function, RAS and SRC gain of function and Bcl-2 gain of function. 11 In addition, androgens can stimulate autocrine tyrosine kinase signalling pathways involving epidermal growth factor receptors (eg HER2 neu), which may lead indirectly to VEGF upregulation. 12 VEGF expression may also be upregulated by Cox-generated PGE 2 . 13 Moreover, human tumours can induce stromal cells to produce significant amounts of VEGF.
14 In growing tumours, the distance from the supporting capillaries increases as cells multiply and tumour mass increases. When cells in the tumour mass grow too far from their blood supply, diffusion becomes insufficient for nutrient requirements and cells begin to die. This results in an equilibrium between the production of new cells in close proximity to the capillaries and the death of existing cells more than 1-2 mm from a blood supply. 15 This equilibrium can apply to a stable carcinoma, which may exist for months or even years before changes leading to more invasive growth occur. One of the switches from a stable carcinoma to a more invasive phenotype occurs when a population of tumour cells develops the necessary cytokine-signalling mechanisms to induce neovascularisation, and the hypoxic or hypoglycaemic environment frequently experienced by tumours can result in upregulation of VEGF. 16 Newly formed tumour blood vessels differ substantially from normal capillaries in several ways that make them accessible targets for antiangiogenic therapy. [17] [18] [19] [20] Some tumour vessels have a defective cellular lining composed of disorganised, loosely connected, branched, overlapping or sprouting endothelial cells. 21 Tumour-induced neovasculature exhibits increased expression of receptors for angiogenic factors, and angiogenic endothelial cells proliferate up to 50 times more than normal endothelial cells. 17, 22 Increases in VEGF, as well as in other angiogenic factors, have been shown to correlate with a worse prognosis in multiple solid tumours and direct measurement of angiogenesis via microvessel density (MVD) assays has also correlated negatively with prognosis in multiple cancers, including prostate. [23] [24] [25] [26] [27] VEGF expression and intratumoural MVD both correlate with decreased survival in men with prostate cancer, and MVD correlates with disease progression after radical prostatectomy. [26] [27] [28] There is evidence that plasma levels of VEGF are increased in patients with metastatic prostate cancer 29, 30 and that anti-VEGF antibodies can prevent the growth of in vivo prostatic tumour models beyond the initial prevascular growth phase.
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The effects of hormones and hypoxia on angiogenesis Data addressing the stimulatory effect of androgens on angiogenesis suggest a possible role for androgens themselves as angiogenic survival factors in prostate cancer. In the prostate, testosterone stimulates angiogenesis in the ventral prostate and vascular regrowth in castrated adult rats, 33 with 1-2% of the endothelial cells in the intact ventral prostate proliferating, a process in which VEGF is likely implicated; castration downregulates VEGF in normal tissues as well as in malignant prostatic tissue, an effect that is reversed by testosterone. 10, 34, 35 In both tumour xenografts and primary human tumours, the neovasculature contains a sizeable fraction of immature blood vessels, characterised by a lack of formed periendothelial cells, which undergo selective apoptosis in the absence of VEGF. 36 In hormone-responsive prostate cancer, VEGF expression is regulated by androgens: androgen deprivation leads to decreased VEGF mRNA and protein expression in LnCaP cells, and castration of mice bearing LnCaP tumours results in a rapid decrease in mRNA expression and markedly reduced tumour neovascularisation. 9, 10 In an androgen-dependent prostate cancer model (Shionogi carcinomas in castrated, severe combined immunodeficient (SCID) mice), androgen withdrawal has been shown to stimulate apoptosis in conjunction with tumour regression and decreased VEGF: on androgen withdrawal, tumour cell apoptosis is preceded by apoptosis of endothelial cells, resulting in tumour vessels adopting more normal vascular characteristics (ie, reduced diameter, tortuosity, vascular permeability and leukocyte adhesion). 37 In this system, 2 weeks after castration, extensive angiogenesis and tumour growth occured, followed by apoptotic effects with a concomitant increase in VEGF expression, suggesting a mechanism for relapse following hormone ablation. 37 Most recently, it was shown that anti-VEGF treatment inhibits testosterone-stimulated prostate growth in castrated mice. 38 Although angiogenic signalling molecules differ in their regulation by androgens (eg, castration was found to inhibit VEGF, but not bFGF, in the androgenresponsive PC-82 and A-2 human prostatic cancers when grown in SCID mice 9 ), when taken together, these reports suggest that androgen withdrawal leads to vascular regression. This regression occurs by downregulation of VEGF expression in normal and malignant cells, firstly causing apoptosis of endothelial cells of immature vessels and then by contributing to the formation of a Hypoxic conditions create a microenvironment in which tumour cells become less dependent on angiogenesis, but more resistant to apoptosis, more capable of existing under hypoxic conditions and more malignant because of the development of genomic instability and mutant genotypes impacting on apoptosis/survival signalling pathways. 40 Hypoxia is present in localised prostate cancer: by measuring the partial pressure of oxygen using Eppendorf pO 2 microelectrodes, regions of prostate cancer have been shown to be hypoxic when compared with areas of normal prostate or adjacent muscle. 41, 42 Oxygen measurements from the pathologically involved portion of the prostate were significantly lower than those from normal muscle. Similarly, higher pO 2 readings were obtained from pathologically normal prostates (in patients with bladder cancer) compared with the prostates of patients with prostate cancer. 42 This correlation was also significant when pO 2 levels were compared with the overall immunoreactive score, which takes into account staining intensity (r ¼ À0.642, P ¼ 0.018). This was the first study demonstrating a significant association between increasing levels of hypoxia and increased expression of VEGF in human prostate carcinoma.
Hypoxic tumour cells are characterised by the upregulation of the hypoxia-inducible factor-1 alpha (HIF-1a), which, together with the constitutively expressed HIF-1b, forms the heterodimeric transcription factor HIF-1.
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The expression of HIF-1a is regulated by cellular oxygen tension and diverse signal transduction pathways. 46 Genes regulated by HIF-1 may be active in adapting tumours to the highly hypoxic and acidic microenvironments in which they are often found, and fall into four broad categories: angiogenesis-related genes; cell viability-related genes; tumour metabolism-related genes and genes coding for degradative enzymes involved in tumour invasion and metastasis. 47 Hypoxia, via HIF-1a signalling, is the most potent stimulus for induction of VEGF. HIF-1a regulates both hypoxia-and growth factor-induced VEGF expression in tumour cells, and genetic manipulation in human tumour xenograft models has established causal relationships between the level of HIF-1 activity, tumour growth and angiogenesis, 48 although non-HIF-1a-mediated signalling pathways may also be involved. 49 It has recently been shown that upregulation of HIF-1a is an early event in prostate carcinogenesis, which suggests that it may serve as a surrogate marker for detecting premalignant lesions of the prostate. 50 The effects of ionising radiation Several lines of evidence support a role for antiangiogenic effects in explaining the cooperation between androgen suppression and ionising radiation in prostate cancer treatment, and the rationale for combining inhibitors of angiogenesis with ionising radiation has recently been reviewed by Wachsberger et al. 51 Zietman et al 52 demonstrated that androgen deprivation enhances the ability of radiation to eradicate tumours in SCID mice: when radiation was combined with orchiectomy, tumours were significantly more likely to be controlled than when radiation was used alone. Androgen deprivation beginning 12 days prior to radiation produced a significantly greater decline in the dose of radiation needed to control tumours than androgen deprivation beginning 1 day or 12 days after radiation. In Lewis lung carcinomas (LLC) growing in syngeneic mice, the efficacy of experimental radiation therapy was found to be potentiated by brief exposure to angiostatin, and ionising radiation-induced VEGF in LLC both in vivo and in vitro. 53, 54 Ionising radiation-induced killing of human umbilical vein endothelial cells (HUVEC) was potentiated by anti-VEGF antibody and decreased by the addition of VEGF, leading investigators to propose a model whereby ionising radiation induction of VEGF contributes to tumour radioresistance. 54 Although ionizing radiation may induce VEGF in tumors, over a protracted fraction schedule, the destruction of the microvasculature results in an antiangiogenic effect. Using cell culture systems, Abdollahi et al 55 reported a potent antiangiogenic effect for ionising radiation, inhibiting endothelial cell survival, but showed that VEGF and bFGF were able to reduce the radiosensitivity of endothelial cells. However, in PC3 tumour cells, radiation induced angiogenic factor production (that was abrogated by the addition of antiangiogenic agents), suggesting a radiation-inducible protective role for tumour cells in support of their associated vasculature. In a genetic investigation of the role of VEGF in the tumour response to ionising radiation in RAS-transformed murine fibrosarcoma cell lines, Gupta et al 56 showed that VEGF þ / þ xenografts were more resistant to the cytotoxic effects of ionising radiation than VEGFÀ/À xenografts. Antitumour strategies targeting VEGF and other endothelial cell survival mechanisms may enhance the cytotoxic effects of radiation therapy. Indeed, in combination with a small-molecule VEGF receptor tyrosine kinase inhibitor, ionising radiation abrogated VEGF-dependent proliferation in HUVEC in a dose-dependent way. Also, combined treatment exerted a substantial, more than additive tumour growth delay and decrease in MVD for radiation-resistant P53-dysfunctional tumour xenografts derived from SW480 colon adenocarcinoma cells, supporting a model of a cooperative antitumoral effect between angiogenesis inhibition and irradiation. 57 These data suggest that cooperation between androgen suppression and radiation in the treatment of prostate cancer may be the result of anti-VEGF activity by antiandrogen therapy, resulting in potentiation of Antiangiogenesis and radiation therapy WA Woodward et al ionising radiation-induced lethality. Studies that have examined factors upstream of VEGF have suggested additional benefits of VEGF-targeting by hormonal therapy. One such factor, HIF-1, mediates a response to hypoxia partly through the transcriptional activation of several genes including VEGF. [58] [59] [60] Increased expression of HIF-1a in rat and human prostatic carcinoma cell lines is associated with increased cell growth rates and metastatic potential. [61] [62] [63] In addition, HIF-1a is also expressed in normoxic cancer cells, suggesting that HIF-1a may be dysregulated in prostate cancer and thus drive the transcription of hypoxia-adaptive genes such as VEGF. Loss or inactivation of P53, PTEN or pVHL or oncogenic activation can all lead to increased HIF-1 activity, providing cancer cells with survival and proliferation advantages to promote the formation of vascular tumours. 64 Why, then, does antiangiogenic activity mediated by hormone ablation enhance the effects of radiation? It is known that hypoxic cells are radioresistant, requiring 2-3 times more radiation to kill them, 65 that hypoxic regions exist in human prostate carcinoma and that tumour hypoxia is an independent prognostic indicator of poor outcome in prostate and other tumours. 41, 66, 67 Radioresistance may therefore arise because of the hypoxic tumour microenvironment. 68 There is evidence to suggest that, paradoxically, antiangiogenic therapy may actually increase delivery of oxygen to the tumour by reducing vascular permeability, which allows for increased oxygen delivery by more normal vasculature. [69] [70] [71] [72] [73] Therefore, an additive effect between radiation therapy and androgen ablation in prostate cancer may arise by a mechanism whereby decreased VEGF expression, resulting from androgen ablation, leads to endothelial cell death in immature tumour vessels, decreased tumour hypoxia and radiosensitisation of tumour cells. Such a model may account for the apparent additivity between hormonal therapy and EBRT for the treatment of prostate cancer.
Conclusions
Advances in angiogenesis research have identified promising targets for therapeutic intervention in the treatment of cancer, including prostate cancer. Angiogenic cytokines such as VEGF have been identified in prostatic cells and tumours, and androgens appear to stimulate VEGF. The stimulatory impact of androgen on VEGF is significant, and there is compelling evidence that part of the antitumour effect of antiandrogen therapy is mediated by its downregulatory effect on VEGF. Both androgen suppression and anti-VEGF treatment target pathological neovasculature, which may result in increased oxygen delivery to hypoxic tumour areas (Figure 1) 
